The Medexprim Suite™ extracts, aggregates, curates, enriches, and deidentifies imaging and clinical data to create regulatory-grade, multicentric, multiomic datasets for clinical research projects. The company provides its GDPR-compliant solution to a network of European university hospitals and cancer centres. Founded in 2016, contextflow offers comprehensive computer-aided detection support for ILD, COPD and lung cancer. Its core product, ADVANCE Chest CT, detects, quantifies, and visualises lung nodules and critical lung disease patterns.
In 2023 Medexprim will produce a European highly curated dataset of 3000 non-small cell lung cancer (NSCLC) cases with aggregated diagnostic and follow-up images contextualised with clinical data. contextflow ADVANCE Chest CT fully integrates into Medexprim Suite™ and is able to analyze this longitudinal collection of CT scans, automatically label these images and indicate treatment efficacy by measuring disease progression over time.
The partnership will enable both the retrospective analysis of a patient images along with their profiles, treatment history, and treatment response. Future training of the model will allow for better diagnosis and prognosis.
Regarding the partnership, Romain Cazavan, CEO of Medexprim, says: “contextflow can be used in daily routine care to detect and measure lung nodules and many more patterns, but it also can be used longitudinally to better understand the progression of the disease compared to treatment. In the future, we would like to be able to predict potential disease regression and offer proactive advice for adapting treatment. Patient timeline is key, and our mutual expertise acts as a wonderful sandbox to streamline routine care.”
Marcel Wassink, CCO at contextflow, continues: “Innovation in medical diagnosis and care is often difficult and slow partly due to the lack of curated data. With this partnership with Medexprim, we are happy to contribute to the faster curation of large imaging data sets and help speed up the realization of new innovations in the market.”